Diplomat Pharmacy (DPLO) Upgraded by Zacks Investment Research to “Hold”

Share on StockTwits

Zacks Investment Research upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a sell rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

Separately, ValuEngine lowered shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $24.50.

DPLO traded up $0.04 during trading on Tuesday, reaching $16.09. The company had a trading volume of 1,694,581 shares, compared to its average volume of 1,097,092. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.95. Diplomat Pharmacy has a 12 month low of $13.31 and a 12 month high of $28.74. The firm has a market cap of $1.10 billion, a P/E ratio of 19.15 and a beta of 0.95.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.21). Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.42 billion. During the same period in the previous year, the firm posted $0.01 EPS. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Diplomat Pharmacy will post 0.81 earnings per share for the current fiscal year.

In other news, Director Philip R. Hagerman sold 209,367 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Philip R. Hagerman sold 57,500 shares of the business’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. Insiders own 24.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in DPLO. Public Employees Retirement Association of Colorado raised its position in Diplomat Pharmacy by 142.2% during the third quarter. Public Employees Retirement Association of Colorado now owns 6,307 shares of the company’s stock worth $122,000 after acquiring an additional 3,703 shares in the last quarter. UBS Group AG raised its position in Diplomat Pharmacy by 186.4% during the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock worth $171,000 after acquiring an additional 5,526 shares in the last quarter. United Services Automobile Association bought a new stake in Diplomat Pharmacy during the second quarter worth $210,000. D.A. Davidson & CO. bought a new stake in Diplomat Pharmacy during the second quarter worth $215,000. Finally, Dorsey & Whitney Trust CO LLC raised its position in Diplomat Pharmacy by 32.4% during the third quarter. Dorsey & Whitney Trust CO LLC now owns 11,397 shares of the company’s stock worth $221,000 after acquiring an additional 2,790 shares in the last quarter. 82.05% of the stock is currently owned by institutional investors and hedge funds.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rayonier Inc.  Holdings Reduced by Forsta AP Fonden
Rayonier Inc. Holdings Reduced by Forsta AP Fonden
Zacks: Brokerages Expect DiamondRock Hospitality  to Announce $0.26 Earnings Per Share
Zacks: Brokerages Expect DiamondRock Hospitality to Announce $0.26 Earnings Per Share
Granite Investment Advisors LLC Cuts Stake in Honeywell International Inc.
Granite Investment Advisors LLC Cuts Stake in Honeywell International Inc.
Forsta AP Fonden Reduces Position in Waste Connections Inc
Forsta AP Fonden Reduces Position in Waste Connections Inc
Edgestream Partners L.P. Acquires 11,229 Shares of Tapestry Inc
Edgestream Partners L.P. Acquires 11,229 Shares of Tapestry Inc
Edgestream Partners L.P. Takes $719,000 Position in SunTrust Banks, Inc.
Edgestream Partners L.P. Takes $719,000 Position in SunTrust Banks, Inc.


Leave a Reply

© 2006-2018 Ticker Report